HEALTH● LOW17h ago · Oct 24, 2026, 5:45 AM
Moderna - Merck personalized mRNA melanoma vaccine cuts relapse risk in late - stage trial
wgxa.tv · United States · global
A personalized mRNA melanoma vaccine developed by Moderna and Merck has shown to reduce the risk of relapse in a late-stage trial. This development could significantly impact melanoma treatment.
GlobeAlert aggregates and classifies open sources; the story above belongs to its publisher. Summaries are machine-generated from the source text.
See it on the live mapUnited States and nearby eventsMore from United StatesLatest stories and threat level
More from United States
POLITICS4h agoALÇUFROM : What the United States gets wrong about France student protests - The Cavalier Daily - University of Virginia Student Newspapercavalierdaily.com · United StatesWORLD10h agoLionel Messi's frantic 72 hours: after revolutionizing Oviedo and receiving the Princess of Asturias, he flew to the United States and plays today for the MLSClarínWORLD12h agoThe prestigious ocean liner SS United States will sink to the bottom of Florida to become a natural reef for hundreds of marine speciesClarínPOLITICS14h agoWho is Abdul El-Sayed, the progressive Muslim doctor seeking to make history in the United States SenateClarín
More in Health
HEALTH11m agoWoman whose cancer was almost missed wants breast density reporting in screeningrnz.co.nzHEALTH1h agoMeet the volunteers helping adults navigate their healthCBS NewsHEALTH1h agoDr . Samuel Esterson : Suburban Orthodox Toras Chaim Retiree Providing Medical Care in Israeljewishtimes.com · United StatesHEALTH1h agoBreast cancer impacting more young women every year, studies showCBS News